Healthy, mtDNA-mutation free mesoangioblasts from mtDNA patients qualify for autologous therapy.

ABSTRACT:

Background

Myopathy and exercise intolerance are prominent clinical features in carriers of a point-mutation or large-scale deletion in the mitochondrial DNA (mtDNA). In the majority of patients, the mtDNA mutation is heteroplasmic with varying mutation loads between tissues of an individual. Exercise-induced muscle regeneration has been shown to be beneficial in some mtDNA mutation carriers, but is often not feasible for this patient group. In this study, we performed in vitro analysis of mesoangioblasts from mtDNA mutation carriers to assess their potential to be used as source for autologous myogenic cell therapy.

Methods

We assessed the heteroplasmy level of patient-derived mesoangioblasts, isolated from skeletal muscle of multiple carriers of different mtDNA point-mutat

SUBMITTER: van Tienen F 

PROVIDER: S-EPMC6925445 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature